What is the translation of " PRESENTED IN MODULE " in Slovenian?

• predstavljenem v modulu
• predloženem v modulu
• predstavljen v modulu
• predstavljeni v modulu
• predstavljenega v modulu
• predložen v modulu

Examples of using Presented in module in English and their translations into Slovenian

Module 2 looks in more depth at the ideas presented in Module 1.
Vsi ostali moduli podrobneje razdeljujejo posamezne ideje, ki so predstavljene v Modulu 1.

Presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.
Ki je bila predstavljena v modulu 1. 8. 1 vloge za dovoljenje za promet, vzpostavljen in bo deloval pred začetkom prometa z zdravilom in dokler bo zdravilo na trgu.

The MAH must ensure that the system of pharmacovigilance presented in Module 1.8.1.
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, predložen v modulu 1.8.1.

The MAH must ensure that the system of pharmacovigilance presented in Module 1.8.1. of the MedicinalMarketing Authoris tion is in place and functioning before and whilst the medicinal product is on the market.
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, predložen v modulu 1.8.1 dovoljenja za promet z zdravilom, vzpostavljen in deluje, preden da.

The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in Version 5 of the Risk Management Plan(RMP) presented in Module 1.8.2. of the Marketing Authorisation Application and any subsequent updates of the RMP agreed by the CHMP.
Imetnik dovoljenja za promet z zdravilom se obvezuje, da bo opravil dodatne farmakovigilančne aktivnosti, podrobno opisane v načrtu farmakovigilance, sprejetem v različici 5 načrta za obvladovanje tveganja(RMP), predstavljenem v modulu 1. 8. 2 vloge za pridobitev dovoljenja za promet z zdravilom in vseh nadaljnjih posodobitvah RMP, s katerimi soglaša CHMP.

The MAH must ensure that the system of pharmacovigilance, presented in Module 1.8.1 of the marketing authorisation, is in place and functioning before the product is placed on the market and for as long as the marketed product remains in use.
Imetnik dovoljenja za promet mora zagotoviti, da je sistem farmakovigilance, predložen v modulu 1.8.1 dovoljenja za promet vzpostavljen in deluje, preden začne tržiti cepivo in ves čas trženja cepiva.

The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in the version dated 18 April 2006 of the Risk Management Plan(RMP) presented in Module 1.8.2. of the Marketing Authorisation and any subsequent updates of the RMP agreed by the CHMP.
Imetnik dovoljenja za promet z zdravilom se zavezuje, da bo izvajal študije in dodatne farmakovigilančne aktivnosti, podrobno opisane v načrtu farmakovigilance, sprejetem v različici z dne, 18. aprila 2006, načrta za obvladovanje tveganja(RMP), predstavljenem v Modulu 1.8.2 vloge za pridobitev dovoljenja za promet z zdravilom in vseh nadaljnjih posodobitvah RMP s katerimi soglaša CHMP.

Dated 17 January 2008 of the Risk Management Plan(RMP) presented in Module 1.8.2. of the Marketing Authorisation and any subsequent updates of the RMP agreed by the CHMP.
Z dne 17. januarja 2008, Načrta ukrepanja v primeru tveganja, predstavljenega v Modulu 1. 8. 2 Dovoljenja za promet in katerihkoli naknadnih posodobljenenih Načrtov ukrepanja v primeru tveganja, ki ga je sprejel CHMP.

The MAH shall perform the pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in the RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.

The MAH must ensure that the system of pharmacovigilance, presented in Module 1.8.1. of the Marketing Authorisation, is in place and functioning before and whilst the product is on the market.
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, kot je predložen v modulu 1.8.1. vloge za pridobitev dovoljenja za promet z zdravilom, vzpostavljen in deluje pred in med prisotnostjo zdravila na trgu.

The MAH shall perform the pharmacovigilance activities as agreed in the RMP presented in Module of the Marketing Authorisation and any subsequent updates.
Imetnik dovoljenja za promet z zdravilom bo izvedel farmakovigilančne aktivnosti, sprejete v RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih posodobitvah.

The MAH must ensure that the system of pharmacovigilance presented in Module 1.8.1 of the Marketing Authorisation, is in place and functioning before and whilst the medicinal product is on the market.
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, ki je predložen v modulu 1.8.1 vloge za pridobitev dovoljenja za promet z zdravilom, vzpostavljen in deluje, preden da zdravilo v promet in ves čas trženja zdravila.

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih posodobitvah RMP.

The MAH must ensure that the system of pharmacovigilance, as described in version 2.0 presented in Module of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, kot je opisan v različici 2.0 in predložen v modulu 1.8.1. vloge za pridobitev dovoljenja za promet z zdravilom, vzpostavljen in deluje, preden da zdravilo v promet in ves čas trženja zdravila.

The MAH shall perform the pharmacovigilance activities detailed in the Pharmacovigilance Plan and the Efficacy Follow-up Plan as agreed in the Risk Management Plan presented in Module 1.8.2. of the Marketing Authorisation Application and any subsequent updates of the RMP agreed by the Committee for Medicinal Products for Human Use(CHMP).
Imetnik dovoljenja za promet z zdravilom bo izvedel farmakovigilančne aktivnosti, podrobno opisane v načrtu farmakovigilance in v načrtu spremljanja učinkovitosti, sprejetem v RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih posodobitvah RMP v soglasju z Odborom za zdravila za uporabo v humani medicini(CHMP).

Pharmacovigilance system The MAH must ensure that the system of pharmacovigilance, as described in version 3 presented in Module 1.8.1. of the Marketing Authorisation Application, is in place and functioning before and whilst the product is on the market.
Farmakovigilančni sistem Imetnik dovoljenja za promet mora zagotoviti ustrezno delovanje sistema farmakovigilance, kot je opisano v različici 3 predstavljeni v modulu 1. 8. 1. vloge za pridobitev dovoljenja za promet z zdravilom, pred in med trženjem z zdravilom.